Safety of Surgery in benign Prostatic Hyperplasia Patients on Antiplatelet or Anticoagulant Therapy: A Systematic Review and Meta-Analysis
Urology Journal,
Vol. 18 No. 02 (2021),
3 May 2021
,
Page 151-159
https://doi.org/10.22037/uj.v18i02.5974
Abstract
Purpose: The management strategies of anticoagulant (AC) or antiplatelet (AP) therapy in the preoperative period of benign prostatic hyperplasia (BPH) is still controversial. Therefore, a meta-analysis to systematically evaluate the surgical safety for BPH patients on AC or AP therapy was performed.
Materials and Methods: The protocol for the review is available on PROSPERO (CRD42018105800). A literature
search was performed by using MEDLINE, Web of Science, PubMed, Cochrane library, and Embase.
Summarized odds ratios (OR), mean difference (MD) and 95% confidence intervals (CI) were used to assess the
difference in outcomes.
Results: We identified 13 trials with a total of 3767 patients. An intragroup significant difference was found in
bleeding complications and blood transfusions when undergoing transurethral resection of the prostate (TURP). For laser surgery, the intragroup significant difference was found in the result of blood transfusion. Bridging therapy would not cause a higher risk of bleeding complications and blood transfusion during the perioperative period. Besides, no difference existed in operation time, catheterization time, hospitalization, and thromboembolic events.
Conclusion: Patients with BPH on perioperative AC/AP therapy would have a risk of postoperative hemorrhage
after TURP or laser treatments. To reduce the risk of hemorrhage, bridging therapy could be a good choice.
- Transurethral resection of prostate (TURP)
- Laser treatment
- Benign prostatic hyperplasia (BPH)
- Anticoagulant
- Antiplatelet.
How to Cite
References
Reference
Berry S J, Coffey D S, Walsh P C, Ewing LL. The development of human benign prostatic hyperplasia with age[J]. Journal of Urology, 1984,132(3):474-479.
Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients.[J]. Journal of Urology, 2008,180(1):246-249.
Mozaffarian D, Benjamin E J, Go A S, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association[J]. Circulation, 2014,131(4):e29.
Wroclawski M L, Carneiro A, Amarante R D, et al. 'Button type' bipolar plasma vaporisation of the prostate compared with standard transurethral resection: a systematic review and meta-analysis of short-term outcome studies.[J]. Bju International, 2016,117(4):662-668.
Zang Y C, Deng X X, Yang D R, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials[J]. Lasers in Medical Science, 2015,31(2):1-6.
Yin L, Teng J, Huang C J, Zhang X, Xu D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials.[J]. Journal of Endourology, 2013,27(5):604-611.
Treatment of Non-neurogenic Male LUTS | Uroweb[EB/OL]. [2018/2/2]. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/.
Lower urinary tract symptoms in men: management | Guidance and guidelines | NICE[EB/OL]. [2018/2/2]. https://www.nice.org.uk/guidance/cg97/chapter/1-Recommendations#surgery-for-voiding-symptoms-2.
Eken A, Soyupak B. Safety and efficacy of photoselective vaporization of the prostate using the 180-W GreenLight XPS laser system in patients taking oral anticoagulants[J]. J Int Med Res, 2018:1217547041.
Ong W L, Koh T L, Fletcher J, Gruen R, Royce P. Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience[J]. Journal of Endourology, 2015,29(11):1321.
Taylor K, Filgate R, Guo D Y, Macneill F. A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs[J]. Bju International, 2011,108(Supplement s2):45-50.
Knapp G L, Chalasani V, Woo H H. Perioperative adverse events in patients on continued anticoagulation undergoing photoselective vaporisation of the prostate with the 180‐W Greenlight lithium triborate laser[J]. Bju International, 2017,119 Suppl 5(S5):33.
Tyson M D, Lerner L B. Safety of holmium laser enucleation of the prostate in anticoagulated patients.[J]. Journal of Endourology, 2009,23(8):1343-1346.
Dotan Z A, Mor Y, Leibovitch I, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction.[J]. Journal of Urology, 2002,168(2):610-614.
Descazeaud A, Robert G, Lebdai S, et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate[J]. World Journal of Urology, 2011,29(2):211-216.
Nielsen J D, Holm-Nielsen A, Jespersen J, Vinther CC, Settgast IW, Gram J. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study[J]. Scandinavian Journal of Urology & Nephrology, 2000,34(3):194.
Ala-Opas M Y, Grönlund S S. Blood loss in long-term aspirin users undergoing transurethral prostatectomy[J]. Scandinavian Journal of Urology, 1996,30(3):203-206.
Jadad A R, Moore R A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J]. Controlled Clinical Trials, 1996,17(1):1-12.
Wells G A, Shea B J, O'Connell D, et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis[J]. Applied Engineering in Agriculture, 2000,18(6):727-734.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease .[J]. Jnci Journal of the National Cancer Institute, 1959,22(4):719-748.
Dersimonian R, Laird N. Meta-analysis in clinical trials.[J]. Controlled Clinical Trials, 1986,7(3):177-188.
Piotrowicz G, Syryło T, Jedynak R, Zieliński H. Efficacy and Safety of Photoselective Vaporization of the Prostate with 120 W 532 nm Laser in Patients with Benign Prostatic Hyperplasia on Anticoagulation or Antiplatelet Therapy: Observations on Long-Term Outcomes[J]. Photomedicine & Laser Surgery, 2017.
El T M, Jacob J, Bhojani N, Bammerlin E, Lingeman JE. HOLMIUM LASER ENUCLEATION OF THE PROSTATE IN PATIENTS REQUIRING ANTICOAGULATION.[J]. Journal of Endourology, 2016.
Ruszat R, Wyler S, Forster T, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation[J]. European Urology, 2007,51(4):1038-1041.
Meskawi M, Hueber P A, Valdivieso R, et al. Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia[J]. World J Urol, 2018.
Eberli D, Chassot P G, Sulser T, et al. Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents.[J]. Journal of Urology, 2010,183(6):2128-2136.
Bell C, Murdock P K, Morgan R. Thrombotic risk factors associated with transurethral prostatectomy.[J]. Bju International, 1999,83(9):984-989.
Fu W J, Zhang X, Yang Y, et al. Comparison of 2-μm Continuous Wave Laser Vaporesection of the Prostate and Transurethral Resection of the Prostate: A Prospective Nonrandomized Trial With 1-year Follow-up[J]. Urology, 2010,75(1):194-199.
Sandhu J S, Ng C K, Gonzalez R R, et al. Photoselective laser vaporization prostatectomy in men receiving anticoagulants.[J]. Journal of Endourology, 2005,19(10):1196-1198.
.[30]Costello A J, Bowsher W G, Bolton D M, Braslis K G, Burt J. Laser ablation of the prostate in patients with benign prostatic hypertrophy.[J]. British Journal of Urology, 1992,69(6):603-608.
Van Melick H H, van Venrooij G E, Boon T A. Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders.[J]. Journal of Urology, 2003,170(5):1851-1855.
Bolton D M, Costello A J. Management of benign prostatic hyperplasia by transurethral laser ablation in patients treated with warfarin anticoagulation.[J]. Journal of Urology, 1994,151(1):79-81.
Zheng X, Qiu Y, Qiu S, et al. Photoselective vaporization has comparative efficacy and safety among high-risk benign prostate hyperplasia patients on or off systematic anticoagulation: a meta-analysis[J]. World J Urol, 2019,37(7):1377-1387.
Berger J, Robert G, Descazeaud A. Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy.[J]. Current Urology Reports, 2010,11(4):236-241.
Melick H H E V, Venrooij G E P M, Boon T A. Laser Prostatectomy in Patients on Anticoagulant Therapy or With Bleeding Disorders[J]. Journal of Urology, 2003,170(5):1851-1855.
Chakravarti A, Macdermott S. Transurethral resection of the prostate in the anticoagulated patient[J]. British Journal of Urology, 1998,81(4):520-522.
Descazeaud A, Robert G, Azzousi A R, et al. Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review[J]. Bju International, 2009,103(9):1162-1165.
- Abstract Viewed: 85 times
- 5974/pdf Downloaded: 77 times